Centessa Pharmaceuticals (CNTA) News Today → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free CNTA Stock Alerts $9.04 +0.21 (+2.38%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 6:44 PM | markets.businessinsider.comBuy Rating on Centessa Pharmaceuticals Based on Strong Pipeline and Financial HealthMay 13 at 11:05 PM | investorplace.comCNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024May 13 at 4:21 PM | finance.yahoo.comCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024May 13 at 4:10 PM | globenewswire.comCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024May 13 at 12:42 AM | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Increase in Short InterestCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 1,790,000 shares, an increase of 39.8% from the April 15th total of 1,280,000 shares. Based on an average daily volume of 335,100 shares, the days-to-cover ratio is presently 5.3 days. Approximately 3.0% of the company's stock are sold short.April 24, 2024 | seekingalpha.comCentessa: Hemophilia B Data Readout In 2024 Is Major Turning PointApril 24, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume IncreaseCentessa Pharmaceuticals (NASDAQ:CNTA) Sees Unusually-High Trading VolumeApril 24, 2024 | nasdaq.comCentessa Pharma Prices Public Offering Of About 10.81 Mln ADSs At $9.25/ADSApril 23, 2024 | globenewswire.comCentessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesApril 23, 2024 | globenewswire.comCentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesApril 23, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.3%Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 3.3%April 22, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $10.57Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $10.57April 22, 2024 | baystreet.caCentessa Gains on New Product NewsApril 22, 2024 | globenewswire.comCentessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024April 12, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 5.3%Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 5.3%April 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial ResultsApril 11, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Up 6.3%Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 6.3%April 8, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $10.37Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $10.37April 1, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 3.6%Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 3.6%April 1, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recApril 1, 2024 | marketbeat.comBMO Capital Markets Reiterates Outperform Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)BMO Capital Markets reiterated an "outperform" rating and set a $15.00 price objective on shares of Centessa Pharmaceuticals in a research report on Monday.March 29, 2024 | msn.comCNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023March 28, 2024 | finanznachrichten.deCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023March 28, 2024 | finance.yahoo.comCentessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 ResultsMarch 28, 2024 | globenewswire.comCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023March 27, 2024 | finance.yahoo.comCentessa Pharmaceuticals PLC Chief People Officer Sells Company SharesMarch 27, 2024 | insidertrades.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 51,160 Shares of StockMarch 26, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 51,160 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 51,160 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.88, for a total value of $607,780.80. Following the sale, the insider now directly owns 71,525 shares of the company's stock, valued at $849,717. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.March 26, 2024 | finance.yahoo.com7 Biotech Stocks Ready to Ride the Sector’s ResurgenceMarch 25, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 5.6%Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 5.6%March 21, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 52-Week High at $12.41Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High at $12.41March 20, 2024 | wsj.comCentessa Pharmaceuticals PLC ADRMarch 19, 2024 | investing.comCentessa Pharmaceuticals PLC ADR (CNTA)March 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comCNTA Apr 2024 7.500 putMarch 16, 2024 | finance.yahoo.comCNTA Apr 2024 5.000 callMarch 16, 2024 | finance.yahoo.comCNTA Jul 2024 7.500 putMarch 12, 2024 | finance.yahoo.comPrivate equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139mMarch 12, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 6.7%Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 6.7%March 11, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 4%Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 4%March 8, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Purchases 580,500 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Adage Capital Partners GP L.L.C. increased its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 25.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,830,500 shares of theMarch 7, 2024 | markets.businessinsider.comUpgraded Buy Rating and Price Target for Centessa Pharmaceuticals on SerpinPC’s Market PotentialMarch 7, 2024 | marketbeat.comLeerink Partnrs Research Analysts Lower Earnings Estimates for Centessa Pharmaceuticals plc (NASDAQ:CNTA)Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Research analysts at Leerink Partnrs decreased their FY2024 EPS estimates for shares of Centessa Pharmaceuticals in a research note issued on Tuesday, March 5th. Leerink Partnrs analyst D. Risinger now expects that the company will post eMarch 6, 2024 | marketbeat.comLeerink Partnrs Weighs in on Centessa Pharmaceuticals plc's Q1 2024 Earnings (NASDAQ:CNTA)Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Centessa Pharmaceuticals in a report released on Tuesday, March 5th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings of ($0.42) per share forMarch 3, 2024 | marketbeat.comAcuta Capital Partners LLC Acquires New Shares in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Acuta Capital Partners LLC acquired a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the third quarter, according to its most recent filing with the SEC. The fund acquired 323,349 shares of the company's stock, valued at approximately $2,092,000. Centessa Pharmaceuticals mFebruary 22, 2024 | finance.yahoo.comCentessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care ConferenceFebruary 16, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Up 9%Centessa Pharmaceuticals (NASDAQ:CNTA) Trading 9% HigherFebruary 15, 2024 | seekingalpha.comCNTA Centessa Pharmaceuticals plcFebruary 15, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Hits New 52-Week High at $10.55Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 52-Week High at $10.55February 15, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Significant Decrease in Short InterestCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,110,000 shares, a decline of 11.2% from the January 15th total of 1,250,000 shares. Currently, 1.9% of the company's shares are short sold. Based on an average trading volume of 248,800 shares, the short-interest ratio is presently 4.5 days. Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights. Get your free information kit NOW, before it's too late. CNTA Media Mentions By Week CNTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTA News Sentiment▼1.040.56▲Average Medical News Sentiment CNTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTA Articles This Week▼92▲CNTA Articles Average Week Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LQDA News INVA News MGNX News SAVA News TYRA News IMNM News OCUL News ABVX News SPRY News ARQT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHow to Make 100X on the AI BoomInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
